Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes.

M Cebrián, E Yagüe, M Rincón… - The Journal of …, 1988 - rupress.org
M Cebrián, E Yagüe, M Rincón, M López-Botet, MO de Landázuri, F Sánchez-Madrid
The Journal of experimental medicine, 1988rupress.org
In this report, we describe a novel activation antigen that appears very early after T cell
activation and is absent in resting lymphocytes, through which agonistic proliferative signals
can be triggered by mAb binding. It has been designated as activation inducer molecule
(AIM) and is a disulphide-linked heterodimeric structure containing two polypeptide chains
of Mr 33,000 and 27,000. The expression of AIM can be induced by different activation
stimuli such as PMA, PHA, or anti-CD3 mAb, but not by the Ca2+ ionophore A23187, and it …
In this report, we describe a novel activation antigen that appears very early after T cell activation and is absent in resting lymphocytes, through which agonistic proliferative signals can be triggered by mAb binding. It has been designated as activation inducer molecule (AIM) and is a disulphide-linked heterodimeric structure containing two polypeptide chains of Mr 33,000 and 27,000. The expression of AIM can be induced by different activation stimuli such as PMA, PHA, or anti-CD3 mAb, but not by the Ca2+ ionophore A23187, and it precedes the expression of other activation molecules such as 4F2 or the IL-2-R. Once AIM antigens are expressed on lymphocytes after stimulation with submitogenic doses of PMA, the binding of anti-AIM mAbs triggers a strong proliferative response. Furthermore, a comitogenic effect of the anti-AIM mAbs is exerted in the presence of either PHA or anti-CD3 mAb. The activation of lymphocytes through AIM antigens induces both IL-2 and IL-2-R receptor synthesis and is inhibited by anti-IL-2-R mAbs.
rupress.org